Author:
Mitkova Zornitsa,Petrova Guenka
Abstract
Health care systems worldwide are experiencing tremendous financial pressure because of the introduction of new targeted health technologies and medicines. This study aims to analyze and compare public and household healthcare expenditures in Bulgaria during the period 2015–2019, as well as present the major cost-containment measures implied by the government and their probable influence on the overall health care cost. Regulatory analysis of the endorsed cost-containment measures, budget analysis of public and household health care expenditures, and their extrapolations were performed. The regulatory analysis reveals that a large number of measures are introduced and valid until January 2021, considering pharmaceuticals, medical devices, and negotiations between the National Health Insurance Fund (NHIF) and Marketing authorization holders (MAHs). NHIF costs due to pharmaceuticals, food supplements, and medical devices are rising from 2015 to 2019. The overall health expenditures average per household and the average per person also grow in this period. The cost extrapolation reveals that an increase in 3-year periods is expected. Despite the implementation of variety of cost-containment measures in Bulgaria, such as HTA, ERP, discounts, and annual negotiations, The National Health Insurance Fund's (NHIF) spending on pharmaceuticals continues to rise in recent years, and further increases are expected in the next 3 years. The average expenditure per household and per person also increased, which confirms the global trend of rising medicine and outpatient services value.
Subject
Public Health, Environmental and Occupational Health
Reference20 articles.
1. “Health Expenditure in Relation to GDP”;OECD/European,2018
2. Controlling Expenditure Within the Spanish Pharmaceutical Market: Macro- and Micro-Level Policy Approaches;Kanavos,2017
3. Analysis of Differences and Commonalities in Pricing and Reimbursement Systsems in Europe
EspinJ
RoviraJ
2007
4. Informal payments for health services: the experience of Bulgaria after 10 years of formal co-payments;Atanasova;Eur J Public Health.,2014
5. Drug policy in Bulgaria;Dimova;Value Health Reg Issues.,2017
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献